Are Countries Using Global Fund Support to Implement HIV Drug Resistance Surveillance? A Review of Funded HIV Grants | Zendy

Karen Kelley | Zendy; Emily Caudwell | Zendy; Serge Xueref | Zendy; Thuy Huong Ha | Zendy; Silvia Bertagnolio | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Are Countries Using Global Fund Support to Implement HIV Drug Resistance Surveillance? A Review of Funded HIV Grants

Author(s) -

Karen Kelley,

Emily Caudwell,

Serge Xueref,

Thuy Huong Ha,

Silvia Bertagnolio

Publication year - 2012

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir1013

Subject(s) - medicine , human immunodeficiency virus (hiv) , tuberculosis , malaria , documentation , family medicine , immunology , pathology , computer science , programming language

The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) is the largest funder of human immunodeficiency virus (HIV) prevention and treatment programs worldwide. Since 2002, the Global Fund has encouraged grant recipients to implement drug resistance surveillance (DRS) as part of treatment programs. We reviewed documentation of 147 grants funded in 2004-2008 (funding rounds 4-8) to assess grantees' use of funds to support HIV DRS. Overall, 94 grants (64%) described HIV DRS as part of the national treatment program. However, only 32 grants (22%) specifically documented DRS as a grant-funded activity. This review provides baseline information suggesting limited use by countries of Global Fund financing to support HIV DRS. Additional assessment is required to evaluate barriers to using Global Fund grants to support DRS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research